A lipidomics analysis from the randomised EmDia trial finds empagliflozin remodels plasma lipids in type 2 diabetes, raising beneficial LPCs but also harmful ceramides. PICO summary and commentary.
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
An OPTION post-hoc analysis finds indobufen-based antiplatelet therapy after stenting performs consistently regardless of diabetes status, with a similar bleeding advantage. PICO summary and commentary.
Summary: In adults with HFpEF (EF ≥50%), obesity (BMI ≥30 kg/m²), stratified by presence or absence of type 2 diabetes…
A prespecified SUMMIT analysis finds tirzepatide reduces heart-failure events in obese HFpEF regardless of diabetes status, despite less weight loss with diabetes. PICO summary and commentary.
Summary: In adults with uncontrolled type 2 diabetes in China, a mobile app-based intervention significantly improved HbA1c and systolic blood…
The 4-year DAPAHEART follow-up finds dapagliflozin raises coronary flow reserve by 34% and reduces epicardial fat, apparently independent of weight loss. PICO summary and commentary.
An RCT finds triple therapy with a statin, SGLT2 inhibitor, and PCSK9 inhibitor lowers lipids more than monotherapy in ischemic heart disease. PICO summary and commentary.
📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context GLP-1 receptor…
Summary: In patients undergoing laparoscopic sleeve gastrectomy (LSG), a combination of preoperative HDL-C and visceral adipose tissue (VAT) significantly predicted…
Clinical Context Curcumin, the principal bioactive compound in turmeric (Curcuma longa), has been studied extensively for anti-inflammatory, antioxidant, and metabolic…